Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Type 1 Diabetes Mellitus · Dehydration · HALO

HALOZYME THERAPEUTICS

HALOZYME THERAPEUTICS, INC.

HALOZYME THERAPEUTICS patent portfolio — 70 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
12390 El Camino Real, San Diego, California 92130, US HQ
2021 Founded
530 Employees
Public company Type
HALO · NYSE Ticker
Company details
Status
Public
HQ
12390 El Camino Real, San Diego, California 92130, US
Founded
2021
Employees
530
Programs
45
Drugs
33
Patents
70
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

HALOZYME THERAPEUTICS patents

70 pharmaceutical patents indexed for HALOZYME THERAPEUTICS. 0 expire within 24 months.

HALOZYME THERAPEUTICS has 70 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

70 patents

Patent portfolio

Page 1 of 2

  1. US 12421308

    Anti-G-CSF antibodies and uses thereof

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12371685

    PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12264345

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12195773

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12178860

    Hyaluronidase enzyme formulations for high volume administration

    Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12152262

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12123035

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12110520

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12104185

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12104184

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12091692

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12077791

    PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12060590

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12054758

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12049652

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12037618

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12018298

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11952600

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11723959

    Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11584923

    Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11414489

    Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11066656

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11041149

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10898551

    Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

    Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10865400

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10588983

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10328130

    Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10286044

    Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

    Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10265410

    Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10137104

    Combination therapy with an anti-hyaluronan agent and therapeutic agent

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10016491

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9993529

    Stable formulations of a hyaluronan-degrading enzyme

    Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9969998

    Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same

    Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9913822

    Combination therapy with an anti-hyaluronan agent and therapeutic agent

    Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9878046

    Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects

    Expires Mon Jan 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9833498

    Methods of treatment of collagen-mediated diseases and conditions

    Expires Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9775889

    Methods of treatment of cellulite

    Expires Mon Sep 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9683985

    Methods for assessing and identifying or evolving conditionally active therapeutic proteins

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9677062

    Hyaluronidase and factor VIII compositions

    Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9677061

    Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

    Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9562223

    Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP)

    Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9458442

    Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9447401

    PH20 polypeptide variants, formulations and uses thereof

    Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9333244

    Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia

    Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9284543

    Neutral active soluble truncated PH20 polypeptides and uses thereof

    Expires Mon Mar 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9278124

    Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods

    Expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9211315

    Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9034323

    Method for control of post-prandial glucose

    Expires Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does HALOZYME THERAPEUTICS have?

70 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do HALOZYME THERAPEUTICS patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.